NDAORALTABLET
Approved
Apr 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HARMONYL (deserpidine) is an oral tablet antihypertensive agent approved in 1957 as an NDA by AbbVie. It belongs to the rauwolfia alkaloid class of drugs used to treat hypertension. The mechanism of action involves sympathetic nervous system depression, though specific MOA details are not currently documented.
LOE Approaching
As a legacy oral antihypertensive approaching loss of exclusivity with minimal modern commercial investment, career growth on this brand is limited and team sizes are likely contracted.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HARMONYL offers limited career growth as a legacy antihypertensive in decline; roles are predominantly focused on cost containment, compliance, and maintaining existing market share rather than innovation or expansion. This position suits professionals seeking stable, low-stress responsibilities or early-career learners in commercial operations.
Brand Manager
Worked on HARMONYL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.